Research programme: retroviral replicating vector based cancer immunotherapy - Tocagen

Drug Profile

Research programme: retroviral replicating vector based cancer immunotherapy - Tocagen

Alternative Names: RRV-NAO; Toca RNAi

Latest Information Update: 23 Dec 2014

Price : $50

At a glance

  • Originator Tocagen
  • Class RNA
  • Mechanism of Action Gene transference; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 18 Nov 2014 Preclinical pharmacodynamics data in Cancer presented at the Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO-2014)
  • 12 Mar 2014 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top